Skip to main content
Fig. 2 | Molecular Medicine

Fig. 2

From: Anti-Tumor Efficacy of a Novel Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in Human Colon Cancer Models: p53-Dependent and p53-Independent Mechanisms

Fig. 2

Synergistic effects of combination treatment of anti-MDM2 oligo AS and the cancer chemotherapeutic agents on MDM2, p53, and p21 protein levels in LS174T cells in culture. Cells were incubated with 400 nM Oligo AS or ASM in the presence of lipofectin for 24 hr, followed by addition of various concentrations of HCPT (panel I), adriamycin (panel II), or 5-FU (panel III) and incubation for additional 24 hr. At various concentrations, the effects on MDM2, p53, and p21 levels were evaluated following treatment with cytotoxic agents alone (lanes A) or pre-treatment with Oligo AS (lanes B) or Oligo ASM (lanes C). Relative levels of each protein were expressed as percentage of control (lipofectin alone), normalized by corresponding β-actin level.

Back to article page